🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Kong Fanming clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Kong Fanming as lead sponsor. Synced 26 Sep 2026
4Current trials
4Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Kong Fanming is the lead sponsor of 4 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Non-Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting4100%

Trials by phase

  • Not applicable375%
  • Phase 2/3125%
01

Clinical trials sponsored by Kong Fanming

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
NCT07034326 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors
Phase 2/3 Recruiting 2025-01 China
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
NCT07086300 · ClinicalTrials.gov ↗ · Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors
Not applicable Recruiting 2025-07 China
Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NCT07239661 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Electroacupuncture, PD-1 Inhibitors
Not applicable Recruiting 2025-11 China
Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
NCT06548711 · ClinicalTrials.gov ↗ · Postoperative Cough, Lung Cancer
Not applicable Recruiting 2024-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Kong Fanming trials

8 conditions
Non-Small Cell Lung Cancer3Electroacupuncture3PD-1 Inhibitors2Immune Checkpoint Inhibitors1Elderly Patients (>65 Years)1ECOG PS 2 Points1Postoperative Cough1Lung Cancer1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China44

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Non-Small Cell Lung Cancer

SponsorTrials
Sichuan Baili Pharmaceutical15
AstraZeneca13
Merck Sharp & Dohme9
Hoffmann-La Roche7
Daiichi Sankyo5
Hunan Province Tumor Hospital5
Shanghai Pulmonary Hospital, Shanghai, China4
Shanghai Chest Hospital4
BioNTech3
Dizal Pharmaceuticals3

Sponsors with the most current trials registered for this condition.

05

Questions about Kong Fanming trials

How many clinical trials does Kong Fanming sponsor?

Kong Fanming is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Kong Fanming trials recruiting?

Yes. 4 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.